1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Biogen Inc.

Biogen Inc.

BIIB
Biogen Inc.US flagNASDAQ Global Select
209.76
USD
-0.89
- -
30.99BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
29.26
41.05
46.66
52.42
57.73
65.66
76.85
83.56
73.65
70.02
67.97
66.46
67.51
68.19
Basic EPS, GAAP
7.86
12.42
15.37
16.95
11.94
21.62
31.47
24.86
10.44
20.97
8.02
11.21
8.83
5.68
Free Cash Flow per Basic Share
-4.91
11.11
14.14
17.67
12.17
25.87
34.25
22.86
22.43
7.85
8.54
17.28
13.44
16.93
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
36.48
46.08
42.88
56.2
59.63
66.12
76.6
70.21
74.12
93.04
102.14
114.71
124.37
127.61
Tangible Book Value per Share
12.32
21.4
12
21.59
19.39
21.37
23.3
12.16
19.82
40.27
1.5
3.75
17.62
-11.23
Basic Weighted Avg Shares
237
236
231
218
213
205
187
161
149
145
145
146
146
147
Sales/Revenue/Turnover
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,891
10,028
Operating Margin (%)
35.92
40.37
46.59
49.39
45.05
44.61
48.93
33.07
25.57
28.52
18.79
23.57
24.96
19.29
Depreciation Expense
532
688
600
683
1,081
650
465
457
488
518
495
673
780
843
Net Income, GAAP
1,862
2,935
3,547
3,703
2,539
4,431
5,888
4,001
1,556
3,047
1,161
1,632
1,293
835
Effective Tax Rate (%)
24.23
25.08
24.37
25.08
47.94
24.16
16.25
19.66
3.01
17.62
10.43
14.37
16.94
17.48
Profit Margin (%)
26.86
30.25
32.95
32.34
20.69
32.93
40.96
29.76
14.17
29.95
11.81
16.87
13.07
8.32
Working Capital
1,427
2,317
4,123
5,312
4,505
4,346
3,518
3,145
3,558
6,518
3,425
1,928
5,625
3,389
LT Debt
592
580
6,522
6,513
5,935
5,936
4,872
7,828
6,604
6,614
7,188
4,882
6,577
7,555
Total Equity
8,621
10,814
9,375
12,129
12,598
13,032
13,339
10,686
10,960
13,388
14,799
16,716
18,257
18,848
Return on Invested Capital (%)
21.54
28
27.41
24.22
15.36
24.18
30.37
18.59
14.57
12.26
7.76
8.44
8.4
6.18
Return on Capital (%)
21.78
28.62
26.18
22.6
13.66
24.21
31.26
21.56
8.8
17.3
6.56
8.12
6.29
4.16
Return on Common Equity (%)
23.9
30.21
35.15
34.42
20.52
34.54
44.64
33.28
14.41
25.08
8.24
10.36
7.39
4.58

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
800
LT Borrowings
6,287
6,288
7,290
LT Finance Leases
290
273
265
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
148
148
Market Capitalization
25,835
27,060
31,912

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,974
9,190
7,306
Cash, Cash Equivalents & STI
3,816
4,283
1,285
Accounts Receivable, Net
1,867
1,790
2,398
Inventories
2,168
1,949
2,384
Total Current Liabilities
3,349
2,999
3,917
Payables & Accruals
2,974
2,806
2,726
ST Debt
- -
- -
800
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
11.49%
9.22%
Free Cash Flow
8.37%
3.04%
-21.72%
Net Income, GAAP
4.09%
-1.48%
-20.79%
Sales/Revenue/Turnover
-0.48%
-5.68%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,290
2,465
2,466
2,455
9,676
2025
2,431
2,646
2,535
2,279
9,891
2026
2,478
2,736
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
4.01
2.67
1.83
11.21
2025
1.65
4.33
3.18
-0.33
8.83
2026
2.17
0.66
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Christopher A. Viehbacher
Full Time Employees
7,500
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
225 Binney Street Cambridge MA United States of America 02142
IPO Date
Sep 17, 1991
CIK
0000875045
Website
biogen.com
Similar Companies
AstraZeneca PLC (AZN.L)
Shandong Jintai Group Co., Ltd. (600385.SS)
Impact Therap-b (7630.HK)
Orion Oyj (ORINF)
Organon & Co. (OGN)
Otsuka Holdings Co., Ltd. (OTSKY)
Business
Biogen Inc. (BIIB) discovers, develops, manufactures and commercializes therapies for neurological and neurodegenerative diseases, hemophilia, multiple sclerosis (MS), spinal muscular atrophy (SMA), lupus and rare diseases worldwide; core products include Tecfidera and Vumerity (dimethyl and diroximel fumarate) for MS, Avonex (interferon beta-1a), Plegridy (peginterferon beta-1a) and Tysabri (natalizumab) for relapsing MS, Spinraza for SMA, Leqembi for Alzheimer's disease, Skyclarys for Friedreich's ataxia and anti-CD20 therapies such as Rituxan and Gazyva for certain B-cell malignancies and autoimmune conditions. The company, founded in 1978 and headquartered in Cambridge, Massachusetts, operates in the United States, Europe, Asia and other international markets. Recent developments include the completion of its acquisition of Alcyone Therapeutics in November 2025 to bolster rare disease capabilities, a November 2025 collaboration with Dayra Therapeutics featuring a $50 million upfront payment for oral macrocyclic peptides targeting immunology, a February 2025 R&D funding agreement with Royalty Pharma worth up to $250 million for Phase 3 litifilimab in lupus, expansion of Leqembi with U.S. approval of the IQLIK subcutaneous formulation, an agreement to acquire Sage Therapeutics and groundbreaking in September 2025 for a new 580,000-square-foot headquarters at 75 Broadway set for completion in 2028 coinciding with the company's 50th anniversary.

Company News

APIChatGPT

  • globenewswire.com

    Biogen Completes Acquisition of RayThera Inc.

  • defenseworld.net

    Biogen Inc. $BIIB Shares Acquired by Amundi

  • fool.com

    Why Biogen Stock Topped the Market Today

  • seekingalpha.com

    Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript

  • benzinga.com

    Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio

  • zacks.com

    Q2 Earnings Season in Full Swing

  • zacks.com

    Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised

  • zacks.com

    Investors Await Fed Decision Today

  • seekingalpha.com

    Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)

  • zacks.com

    Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

  • marketbeat.com

    Biogen Q2 Earnings Call Highlights

  • zacks.com

    Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

  • gurufocus.com

    Is Biogen Inc (BIIB) Overvalued After Q2 Earnings With EPS of $0.66 and Revenue of $2,736 Million? GF Score: 69/100

  • wsj.com

    Biogen Cuts FY Adjusted View as Profit Declines

  • reuters.com

    Biogen beats quarterly estimates as newer drugs fuel growth

  • barrons.com

    Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs

  • zacks.com

    Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

  • zacks.com

    Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

  • zacks.com

    Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

  • defenseworld.net

    Biogen (NASDAQ:BIIB) vs. Vitro Diagnostics (OTCMKTS:VODG) Critical Contrast